We remain Neutral on Mindray Medical International (NYSE:MR). Its fourth-quarter 2011 earnings per share just missed the Zacks Consensus Estimate.
Mindray is a bellwether for the Chinese medical devices industry. The company has a large domestic sales infrastructure, which gives it better access to medium-sized county hospitals. In China, it beats other multinationals on price and defeats local players, who have cheaper products, on brand recognition.
In western markets, the company targets … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards